CD274 and esophageal squamous cell carcinoma: The phase 3 trial (ATTRACTION-3) showed superiority of nivolumab for the second-line treatment of all ESCC patients regardless of PD-L1 expression (Kato et al., 2019; Kojima et al., 2019).